Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2171 · 16 trials · 21 indications
Number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression.
\[F 18\] Fluoro 2 Deoxy D Glucose - Positron Emission Tomography (FDG-PET). Tumour metabolic activity as assessed by Change in Standardised Uptake Value (SUVMax) at Day 8 (measured by central review), in Patients with GIST tumours. SUVmax at Day 8 minus SUVmax at Baseline.
SUVmax at Day 29 minus SUVmax at baseline, based on central review, GIST patients
Total actual dose received during the first 12 weeks prior to progression divided by the planned dose (planned dose: initial allocated dose multiplied by the number of days on study during the first 12 weeks prior to progression)
Percentage Change from baseline in Standardised Uptake Value (SUVmax) at Day 22, as Measured by 2-\[F-18\]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) Response ((Day 22 SUVmax value - baseline SUVmax value)/baseline SUVmax value)\*100
| Arm | Type | Description |
|---|---|---|
| 2 | ACTIVE_COMPARATOR | Fulvestrant Monotherapy |
| 3 | EXPERIMENTAL | AZD2171 + Fulvestrant |
| 1 | ACTIVE_COMPARATOR | Bevacizumab + FOLFOX |
| FOLFOX + Cediranib 20 mg | ACTIVE_COMPARATOR | FOLFOX + Cediranib 20 mg |
| FOLFOX + Cediranib 30 mg | ACTIVE_COMPARATOR | FOLFOX + Cediranib 30 mg |
| FOLFOX + Placebo Cediranib | PLACEBO_COMPARATOR | FOLFOX + Placebo Cediranib |
| Name | Type | Description |
|---|---|---|
| AZD2171 | DRUG | Oral tablet |
| Fulvestrant | DRUG | intramuscular injection |
| 5-fluorouracil | DRUG | intravenous infusion |
| Leucovorin | DRUG | intravenous infusion |
| Oxaliplatin | DRUG | intravenous infusion |
| Bevacizumab | DRUG | intravenous infusion |
| Etoposide | DRUG | Intravenous |
| Cisplatin | DRUG | Intravenous |
| FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) | DRUG | intravenous infusion |
| Placebo Cediranib | DRUG | oral tablet |
| AZD0530 | DRUG | oral tablet multiple ascending doses 125 mg or 175 mg |
| FOLFOX | DRUG | intravenous infusion |
| Pemetrexed | DRUG | intravenous infusion |
| Irinotecan (administered with & without Cetuximab) | DRUG | intravenous injection |
| Docetaxel | DRUG | intravenous infusion |
| ZD1839 | DRUG | - |
Inclusion Criteria: * Written informed consent * Females with histological/cytological confirmation of hormone sensitive breast cancer with evidence of metastatic disease * One or more evaluable lesions Exclusion Criteria: * Prior hormonal therapy with fulvestrant * More than one course of prior ...
Top 20 of 92 competitors
AZD2171 is an investigational small molecule being studied in oncology. It has been evaluated in clinical trials for metastatic colorectal cancer, advanced breast cancer, non-small cell lung cancer, head and neck cancer, and advanced solid tumors. It is not approved and remains in clinical development.
AZD2171 is a small molecule that targets vascular endothelial growth factor receptors (VEGFR), inhibiting tumor angiogenesis. It is being studied to determine its effects in various advanced cancers, including colorectal cancer and breast cancer.
AZD2171 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is in Phase 2 clinical development for oncology indications.
AZD2171 is in Phase 2 clinical development. It has completed three trials, including Phase 1 and Phase 2 studies, with a total enrollment of 224 participants. The drug is investigational and has not been approved by regulatory authorities.
AZD2171 has completed three clinical trials: NCT00243347 in non-small cell lung cancer and head and neck cancer, NCT00278889 in colorectal cancer, and NCT00454805 in advanced breast cancer. All trials are completed, with no active trials ongoing.
Yes, AZD2171 is also known as cediranib. A completed Phase 1 study, NCT00621725, evaluated cediranib in patients with solid tumors and hepatic impairment. The drug is being developed by AstraZeneca for multiple oncology indications.